Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.57 |
| ▸ | CTSG | P08311 | 2/20 | 0.57 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.57 |
| ▸ | CMA1 | P23946 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MLYCD | O95822 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14636882 | 0.88 | HTT (0.55) | GAAPRSS1CTSGCTRB1CMA1 | |
| SCHEMBL12188582 | 0.86 | EPHX2 (0.50) | GAAPRSS1CTSGCTRB1CMA1 | |
| SCHEMBL28316775 | 0.85 | PRSS1 (0.55) | GAAPRSS1CTSGCTRB1CMA1 | |
| SCHEMBL16215582 | 0.85 | GAA (0.57) | GAAPRSS1CTSGCTRB1CMA1 | |
| SCHEMBL30914530 | 0.85 | PRSS1 (0.63) | GAAPRSS1CTSGCTRB1CMA1 | |
| SCHEMBL6673647 | 0.85 | GAA (0.57) | GAAPRSS1CTSGCTRB1CMA1 | |
| SCHEMBL16156086 | 0.85 | PRSS1 (0.63) | GAAPRSS1CTSGCTRB1CMA1 | |
| SCHEMBL15905185 | 0.84 | LMNA (0.56) | GAAPRSS1CTSGCTRB1CMA1 | |
| SCHEMBL22207618 | 0.83 | GAA (0.55) | GAAPRSS1CTSGCTRB1CMA1 | |
| SCHEMBL30739963 | 0.83 | GAA (0.55) | GAAPRSS1CTSGCTRB1CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4073043-B1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY | CENTESSA PHARMACEUTICALS UK LTD (GB) | 2024-04-03 | — | — | EP | claimed |
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | claimed |
| EP-3303291-A1 | ROR GAMMA (ROR ) MODULATORS | Lead Pharma Holding B.V. (NL) | 2018-04-11 | — | — | EP | claimed |
| EP-3303290-A1 | ROR GAMMA (RORY) MODULATORS | Lead Pharma Holding B.V. (NL) | 2018-04-11 | — | — | EP | claimed |
| CN-105121444-B | Cyano ethyl Pyrazolopyridine ketone as the other than ring type of JANUS kinase inhibitors | 默沙东公司 | 2018-02-16 | — | — | CN | claimed |
| WO-2016193459-A1 | ROR GAMMA (RORY) MODULATORS | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2016-12-08 | — | — | WO | claimed |
| WO-2016193452-A1 | ROR GAMMA (RORγ) MODULATORS | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2016-12-08 | — | — | WO | claimed |
| CN-103608350-B | Triazolopyridine compounds | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-25 | — | — | CN | claimed |
| CN-103608350-A | Triazolopyridine compounds | BAYER IP GMBH | 2014-02-26 | — | — | CN | claimed |
| EP-2507236-A1 | TRIAZOLOPYRIDINE DERIVATIVES | Bayer Intellectual Property GmbH (DE) | 2012-10-10 | — | — | EP | claimed |
| EP-2280966-A1 | AZABICYCLO [3.2.1]OCTYL DERIVATIVES AS 11 BETA-HSD1 MODULATORS | Exelixis, Inc. (US) | 2011-02-09 | — | — | EP | claimed |
| US-20100105675-A2 | 11 BETA-HSD1 MODULATORS | EXELIXIS, INC. (US) | 2010-04-29 | — | — | US | claimed |
| US-20090247515-A1 | 11 Beta-HSD1 Modulators | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | claimed |
| WO-2009114173-A1 | AZABICYCLO [3. 2. I] OCTYL DERIVATIVES AS 11 BETA-HSDL MODULATORS | EXELIXIS, INC. (US) | 2009-09-17 | — | — | WO | claimed |
| WO-2007123853-A2 | FIVE-MEMBERED HETEROCYCLIC INVERTEBRATE PEST CONTROL AGENTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2007-11-01 | — | — | WO | claimed |
| EP-1768960-A1 | SULFONAMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-04-04 | — | — | EP | claimed |
| JP-2006528597-A | — | — | 2006-12-21 | — | — | JP | claimed |
| EP-1658263-A1 | NOVEL AMINOBENZOPHENONE COMPOUNDS | Leo Pharma A/S (DK) | 2006-05-24 | — | — | EP | claimed |
| WO-2006005486-A1 | SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-19 | — | — | WO | claimed |
| WO-2005009940-A1 | NOVEL AMINOBENZOPHENONE COMPOUNDS | LEO PHARMA A/S (DK) | 2005-02-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105675-A2 | 11 BETA-HSD1 MODULATORS | HSD11B1, HSD11B2, HSD3B1 | GAA 1314/4885PRSS1 141/4885CTSG 3909/4885 |
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | MAP3K20, MAP3K15, MAP3K1 | GAA 2187/4885PRSS1 945/4885CTSG 4188/4885 |
| US-20090247515-A1 | 11 Beta-HSD1 Modulators | HSD11B1, HSD11B2, HSD3B1 | GAA 1470/4885PRSS1 123/4885CTSG 3655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.